News

Fulvestrant Adds Punch to Anastrozole for HR+ Breast Cancer

Publish date: December 28, 2011

 

FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Dr. Mehta disclosed receiving grant and research support from AstraZeneca.

Pages

Recommended Reading

Factors Predict Contralateral Breast Cancer Risk in BRCA Carriers
Breast Cancer ICYMI
Breast Cancer Linked to Benign Thyroid Disease
Breast Cancer ICYMI
Meta-Analysis: Pregnancy-Associated Breast Cancer Fares Poorly
Breast Cancer ICYMI
Recent Diabetes Increases Breast Cancer Risk
Breast Cancer ICYMI
Acupuncture Flops as Relief for Muscle Pain From Aromatase Inhibitors
Breast Cancer ICYMI
Oncotype DX Cost Effective, Challenges Breast Cancer Practice
Breast Cancer ICYMI
Vitamin D Deficiency/Breast Cancer Link Questioned
Breast Cancer ICYMI
Metastatic Work-Up Not Needed for All N2/N3 Breast Cancers
Breast Cancer ICYMI
T-DM1 Supports QOL in HER2+ Metastatic Breast Cancer
Breast Cancer ICYMI
Doctors, Patients Disconnected on Aromatase Inhibitor Compliance
Breast Cancer ICYMI